Recap: HOOKIPA Pharma Q2 Earnings

Shares of HOOKIPA Pharma HOOK moved higher by 3.3% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 85.71% over the past year to ($0.52), which beat the estimate of ($0.53).

Revenue of $5,378,000 decreased by 19.55% year over year, which beat the estimate of $5,130,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

HOOKIPA Pharma hasn't issued any revenue guidance for the time being.

Recent Stock Performance

52-week high: $20.00

52-week low: $7.28

Price action over last quarter: down 53.86%

Company Profile

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.